Navigation Links
Bionovo to Present at the Cambria Capital Investor Meeting
Date:3/26/2008

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, is scheduled to present at the Cambria Capital Investor Meeting in Salt Lake City on March 27, 2008 at 4:00 p.m. MDT.

Isaac Cohen, O.M.D., Chairman and CEO, and Mary Tagliaferri, M.D., President and CMO are both scheduled to present, along with Tom Chesterman, SVP and CFO. The purpose of the presentation will be to update investors on the current business developments and goals for 2008.

No webcast or archive will be available for this presentation. Those investors wishing to attend should contact Cambria Capital at (877) 224-0477 toll free, (801) 320-9606 main or by email at clientservices@cambriacapital.com.

About Cambria Capital, LLC

Cambria Capital, LLC ("Cambria") is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria's mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm's principals and Cambria's network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at http://www.cambriacapital.com

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure ... to individuals in need. The event is scheduled to take place on February 27, ... to provide dental care to community members in need. Each patient will be given ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, ... it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the ... oral health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , ...
(Date:2/5/2016)... Pekin, IL (PRWEB) , ... February 05, 2016 , ... ... in disguised form as a dream. A hallmark feature of patients with eating disorders ... and needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile ... the debut of their latest mobile kitchen model, featuring customizable stainless steel interiors ... high-volume commercial kitchens for use anywhere in the U.S. Many of their units ...
(Date:2/5/2016)... Russia (PRWEB) , ... February 05, 2016 , ... Calls ... has a completely new user interface design and the developer has fixed known bugs ... those they want to on their phone while not consuming any of their device’s ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: